BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld

BioWorld

Dec. 16, 2011

View Archived Issues

'BLOOM' off the Rose: LibiGel Failure Sends BioSante Falling

BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., reported disappointing results from its two pivotal Phase III trials of LibiGel (testosterone gel) for hypoactive sexual desire disorder in postmenopausal women. Read More

Post-ASH, Ariad Prices Public Offering, Aims to Raise $224M

On Wednesday, Ariad Pharmaceuticals Inc. filed a shelf registration covering stock, debt securities, warrants and units. The company didn't leave investors in suspense for long. A day later, the company priced an underwritten public offering of 21.5 million shares of common stock at Wednesday's closing price of $10.42 per share, a discount of just 5.4 percent from Tuesday's closing price of $11.01. Read More

Panel: Flexibility Needed to Tackle What-Ifs of Smallpox

WASHINGTON – An FDA advisory committee faced some stark what-ifs this week in developing a treatment for a disease that no longer exists in the natural world. Read More

Orexigen Adding $90M Publicly, Ready for Contrave CVOT Trial

Back in September, Orexigen Therapeutics Inc.'s CEO told BioWorld Today that the firm hoped to avoid a near-term financing by securing an ex-U.S. partnership to help offset costs for the large cardiovascular outcomes trial (CVOT) required by the FDA to get obesity candidate Contrave (naltrexone HCl/buproprion) over the finish line. Read More

Other News To Note

• Dicerna Pharmaceuticals Inc., of Watertown, Mass., said partner Kyowa Hakko Kirin Co. Ltd., of Tokyo, elected to advance the first collaborative oncology candidate from research stage into formal development studies, triggering a $5 million milestone payment. In addition, Kyowa exercised an option to bring a second cancer target into the collaboration. Read More

Stock Movers

Read More

U.S. Patent Disclosures

• Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., received notices for allowance for two patents. The first is directed to a class of compounds combining elements of diketopiperazines and methylphenidate derives, while the second is directed to derivatives of methylphenidate (Ritalin). Read More

Clinic Roundup

• Human Genome Sciences Inc., of Rockville, Md., and GlaxoSmithKline plc, of London, said they started dosing in BLISS-SC, a new Phase III trial of Benlysta (belimumab) administered subcutaneously once weekly to autoantibody-positive adults with active systemic lupus erythematosus (SLE). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing